Allied Market Research

North America Dendritic Cell Cancer Vaccine Market : Opportunities 2017-2023

Dendritic cells (DCs) refer to rare kinds of leukocytes. They are used in therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells.


Portland, OR -- (SBWIRE) -- 09/07/2017 -- An increase in the prevalence of Dendritic Cell cancer and improvement of technology such as drug innovations regarding cancer drive the market growth. However, stringent regulatory procedures restrain the market. Upsurge in the awareness of cancer and their available therapies in the market, along with an increase in healthcare expenditure are expected to provide opportunities for the market growth.

Access full summary at:

This report segments the North American dendritic cell cancer vaccine market based on type, end user, and country. Based on type, it is categorized into CreaVax, Sipuleucel-T (Provenge), and others. Based on end user, it is classified into pediatrics and adults. By country, it has been analyzed across the U.S., Canada, and Mexico.

The key players of the dendritic cell cancer vaccine market are 3M Company, Argos Therapeutics, Creagene, Dendreon Corporation, Elios Therapeutics, ImmunoCellular Therapeutics, Merck & Co., Inc., GlaxoSmithKline plc, Northwest Biotherapeutics, Inc., and Tella Incorporation.

Get PDF Brochure of this report:

North America Dendritic Cell Cancer Vaccine Market Key Segments:

By Product Type

- CreaVax
- Sipuleucel-T (Provenge)
- Others

By End User

- Pediatrics
- Adults

Early buyers will receive 20% customization on this report